Ayeskanta Mohanty

Ayeskanta Mohanty

Auto-generated profile, based on publicly available information

Ayeskanta Mohanty

Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju, 61469, Republic of Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
AMAyeskanta Mohanty
Ayeskanta Mohanty
AMAdityanarayan Mohapatra
Adityanarayan Mohapatra
WYWoojin Yang
Woojin Yang
SCSeunghyun Choi
Seunghyun Choi
ASAravindkumar Sundaram
Aravindkumar Sundaram
IPIn-Kyu Park
In-Kyu Park

1 April 2026 in Materials Today Bio
Verified
Journal Article
Open access
AMAyeskanta Mohanty
Ayeskanta Mohanty
SNSudhanya Nayak
Sudhanya Nayak
AMAdityanarayan Mohapatra
Adityanarayan Mohapatra
YJYong-Yeon Jeong
Yong-Yeon Jeong
CLChang-Moon Lee
Chang-Moon Lee
IPIn-Kyu Park
In-Kyu Park
Recent advances in biomaterials have highlighted the immense potential of carbohydrate polymers (CHPs) as biocompatible, multifunctional platforms for cancer therapy. Indeed, the structural diversity, tunable chemistry, and inherent biological affinity of these polymers enable the precise design of systems for immune modulation. Moreover, light- and laser-driven strategies have emerged as powerful tools for achieving spatiotemporal control over therapeutic activation. Therefore, integrating CHPs with photothermal or photodynamic nanocomponents enables these hybrid systems to induce localized tumor ablation, trigger immunogenic cell death, and remodel the tumor immune microenvironment. These synergistic phototherapy–immunotherapy platforms eradicate primary tumors while promoting systemic antitumor immunity and immune memory formation. Therefore, this review aims to summarize recent advances in CHP-based biomaterials for light-mediated immune activation, focusing on mechanisms, design strategies, and therapeutic outcomes. Furthermore, challenges in tumor-specific targeting, deep-tissue light penetration, and clinical translation are critically discussed. Finally, future perspectives are proposed for the development of next-generation, smart, light-responsive carbohydrate nanomedicines to enable precision cancer immunotherapy.